As the global obesity and diabetes epidemic continues to surge, the demand for effective, safe, and sustainable weight management solutions has never been higher. In the United States alone, millions struggle with type 2 diabetes and obesity, conditions that not only shorten lives but also diminish quality of life. While medications like Ozempic (semaglutide) and other GLP-1 agonists have changed the landscape of diabetes and weight loss therapy, they come with a significant drawback: the loss of precious muscle mass. Now, a groundbreaking drug in development could offer a better way—a true “exercise in a pill” that burns fat, lowers blood sugar, and preserves muscle.

GLP-1 agonists, including Ozempic and Wegovy, have become household names for their dramatic effects on weight loss and blood sugar control. These drugs work by mimicking a gut hormone that signals the brain to reduce appetite and slow gastric emptying, helping people eat less and lose weight. However, studies have shown that up to 60% of the weight lost on these medications can come from lean muscle, not just fat.

In a groundbreaking development that could reshape the weight loss and metabolic disease treatment, researchers from Sweden have introduced an experimental oral drug that mimics the benefits of exercise — without the need for injections, and more importantly, without compromising muscle mass.

Led by a collaboration between the Karolinska Institutet, Stockholm University, and biotech company Atrogi AB, the newly developed β2-adrenergic receptor (β2AR) agonist has shown promising results in burning fat, lowering blood sugar, and preserving lean muscle — a trio of effects that current popular drugs like Ozempic (semaglutide) struggle to achieve simultaneously.

“This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity,” said study lead author Professor Shane Wright from Karolinska Institutet.

Why Muscle Loss Matters in the Weight Loss Drug Debate?

Drugs like Ozempic and Wegovy, classified as GLP-1 receptor agonists, have become increasingly popular for treating obesity and type 2 diabetes. Their efficacy in reducing hunger and slowing gastric emptying has made them a household name. However, several studies have indicated that up to 60% of the weight lost using GLP-1 drugs may be lean muscle mass, not fat. That’s a dangerous trade-off.

Muscle mass isn’t just about strength or athletic performance — it is metabolically active tissue, meaning it burns more calories at rest than fat and plays a crucial role in regulating blood sugar levels. Losing muscle slows metabolism, increases insulin resistance, and can even raise the risk of osteoporosis, particularly in older adults.

The need for a safer alternative has never been greater — and this new pill could be the answer.

This muscle loss isn’t just a cosmetic issue. Muscle tissue is metabolically active, burning more calories at rest than fat. Losing muscle lowers the resting metabolic rate, making it harder to keep weight off long-term. Muscle is also essential for strength, mobility, and healthy aging, and it plays a crucial role in regulating blood sugar. For older adults, muscle loss can accelerate frailty, increase the risk of osteoporosis, and reduce life expectancy.

How This Drug Works?

Unlike GLP-1 agonists, which work through the brain-gut axis by reducing hunger, the new drug directly targets skeletal muscle metabolism. It’s designed to activate β2-adrenergic receptors, simulating the body’s physiological response to physical exercise. This boosts the metabolism of muscle tissue and promotes fat burning without suppressing appetite or causing lean tissue degradation.

In animal studies, the compound was shown to improve body composition, reduce fat mass, and preserve or even enhance muscle tissue. These results were so promising that researchers quickly moved into a Phase I human clinical trial

“Our substance appears to promote healthy aging and weight loss—and, in addition, patients do not have to take injections,” said Professor Shane Wright of the Karolinska Institutet, one of the study’s lead authors.

Early Human Trials

The Phase I trial included 48 healthy volunteers and 25 people with type 2 diabetes, all of whom were administered a 2.5 mg daily dose of the tablet for 28 days. Participants’ key health metrics — including heart rate, blood pressure, and glucose levels — were closely monitored.

The results were encouraging. Both healthy participants and those with diabetes tolerated the drug well. The only notable side effect was a mild, transient increase in heart rate early in the trial, which resolved by day 28. Importantly, there were no significant differences in heart rate or blood pressure between the groups by the end of the study.

One participant experienced a severe adverse event, but this occurred in someone with preexisting cardiac abnormalities and resolved without complications. The connection to the study drug remains uncertain, and overall, the safety profile appears favorable.

At the end of the trial, all participants had plasma drug levels consistent with therapeutic dosing, confirming compliance and supporting the validity of the safety data.

Why is the Drug Different From Ozempic and Other GLP-1 Agonists?

The most significant advantage of this new β2-agonist is its ability to preserve muscle mass during weight loss. While GLP-1 drugs work primarily by reducing caloric intake, often at the expense of muscle, the new drug targets muscle metabolism directly. This distinction could be transformative, especially for older adults, people with chronic illnesses, and anyone concerned about muscle health.

“Muscles are important in both type 2 diabetes and obesity—and muscle mass is also directly correlated with life expectancy,” said Professor Tore Bengtsson, a molecular biologist at Stockholm University and co-author of the study. “Our results point to a future where we can improve metabolic health without losing muscle mass.”

With phase 1 safety data in hand, the research team is moving forward with larger, longer phase 2 trials. These studies will focus on the drug’s effects on muscle mass, glucose control, insulin sensitivity, and overall metabolic health in people with type 2 diabetes and obesity. If successful, this new therapy could become a first-in-class oral medication that offers the benefits of exercise—without the need for injections or the risk of muscle loss.

Is This A Non-Injection Weight Loss Future?

Aside from its unique muscle-preserving benefits, another major selling point is its oral delivery. Unlike Ozempic or Mounjaro, which require regular injections, this pill is taken once daily, making it easier to incorporate into everyday life — a feature that could improve adherence, accessibility, and affordability.

This shift could democratize weight loss and diabetes management therapies, especially for patients who are needle-averse or face barriers to injectable drug regimens.

The development of an “exercise in a pill” is more than just a scientific curiosity—it represents a paradigm shift in how we approach chronic metabolic diseases. For millions who struggle to exercise due to physical limitations, age, or illness, such a drug could provide life-changing benefits. Even for those who can be active, combining this therapy with lifestyle changes could amplify results.

However, experts caution that no pill can fully replace the wide-ranging benefits of physical activity, which include cardiovascular health, mental well-being, and bone strength. Still, the potential to safely burn fat and preserve muscle—especially for vulnerable populations—marks a significant leap forward.

Autism in women is not often entirely recognized because this disorder does not always have to correspond to the “classic” picture characteristic of males.

The diagnosis is based on a male criterion with such behavior as obvious withdrawal from a group, overtly displayed repetitive behaviour, and limited interests. There can be mild social deficit or internalized anger and frustration that can pass unnoticed in clinical practice.

The Art of Masking

One of the most significant reasons behind underdiagnosis is masking (also called camouflaging). Masking is one of the most significant reasons for underdiagnosis. This is helpful in masking but also covers or conceals essential symptoms.

Masking causes mental exhaustion, anxiety, and burnout, but it does not address the underlying autism and leaves it undiagnosed.

Stereotypes And Gender Bias

There is a strong societal stereotype that autism is a “male condition”. This bias is felt by parents, teachers, as well as health care professionals.

Sex bias is evident in that boys get referred for evaluation early. Girls are often tagged “shy,” “sensitive,” and “introverted.”

Their struggles are normalized instead of being explored for any issues. Gender bias is a significant contributor to delayed or wrong diagnosis.

Different Interests, Less Suspicion

A restricted interest is another hallmark of autism, but in women, it tends to be more socially acceptable. Their interests conform to the norms of society; they do not predispose clinical suspicion as opposed to more masculine interests like mechanical systems or numbers.

Overlap With Other Conditions

Autism in women being misdiagnosed as other psychiatric disorders is due to symptom comorbidity. Some of the common misdiagnoses are:

• anxiety disorders,
• major depressive disorder,
• borderline personality disorder,
• eating disorders.

In many cases, these are secondary to autism as a result of years of living with undiagnosed autism.

Social Expectations And Conditioning

From an early age, girls are often conditioned to be socially attentive, empathetic, and compliant. This societal conditioning pushes autistic girls to adapt and hide their difficulties.

These may include forcing themselves into socializing. Fitting in is deemed more important than comfort. They end up creating coping mechanisms that mask their difficulties.

While this may benefit outward functioning, it postpones the recognition of underlying neurodevelopmental differences.

The Consequences of Late Diagnosis

Delayed diagnosis or missed diagnosis has the following effects:

• Chronic mental illness
• Low self-esteem
• Confusion about identity
• Inadequate support services

The World Health Organization estimates that 10 percent (190 million) of reproductive-age women worldwide suffer from endometriosis.

The chronic and complex menstrual disease that affects many women is characterized by severe pain during menstruation, heavy menstrual bleeding, chronic pelvic pain (pain that does not go away when the menstrual cycle ends), infertility, and abdominal bloating and nausea.

The incurable condition poses a significant challenge to women as it affects their personal and professional lives, relationships, and fertility, among others, due to persistent pain and fatigue.

The diagnosis also gets delayed, as endometriosis is often confused with PCOS, or Polycystic Ovary Syndrome, due to some overlapping symptoms like irregular menstrual periods. The symptoms may continue to persist or recur after treatment is initiated.

In a powerful statement resonating with millions worldwide, Indian American author and television host Padma Lakshmi has shared her experience with the condition.

Opening about her personal battle with endometriosis, the 55-year-old, Co-founder of Endometriosis Foundation of America, said that the condition made her understand how strong she is and called for greater awareness and self-advocacy among women.

"Endometriosis has taught me that I should always listen to my body. Pain is your body's way of telling you something is wrong,” said Lakshmi, in a media post on social media platform Instagram.

"Through my struggles with endometriosis, I've learned that, actually, I have a very high threshold for pain, that I may be stronger than I know, but that I shouldn't always need to be,” PopSugar quoted her as saying.

Lakshmi noted that it is now her life's mission "to advocate for my own health, and also to advocate for all women with endometriosis."

What Is Endometriosis?

Endometriosis happens when tissue similar to the lining of the uterus grows outside the uterus. These tissues commonly develop on the ovaries, fallopian tubes, or the pelvic lining.

Endometriosis affects many women and can impact their daily lives, including their ability to work comfortably. Many women continue their professional responsibilities despite experiencing severe discomfort, fatigue, and pain.

Raising awareness about the condition and encouraging supportive workplaces can help women manage both their health and career more effectively.

Since it is a progressive disorder, timely intervention remains key to managing it. In many cases, women live with symptoms for several years before receiving the correct diagnosis, which can delay treatment and affect their quality of life.

Treating Endometriosis

Treatment is particularly based on the severity of symptoms. Women will be advised lifestyle modifications such as regular exercise, stress management, and an anti-inflammatory diet. Non-steroidal anti-inflammatory drugs may help reduce discomfort.

Hormonal therapies may also be used to control symptoms. Some women will be advised to undergo laparoscopy to remove endometriotic cysts.

Minimally invasive surgery can help remove lesions and restore pelvic anatomy, which may also improve fertility in some cases. In advanced cases, surgery can be recommended to women.

In a shocking incident, a woman contracted the herpes virus after using shared lipstick samples at a cosmetic store, raising concerns about makeup hygiene.

The incident highlights the risks involved in trying products that come into direct contact with the skin and are shared with a lot of people.

Also Read: World Autism Awareness Day 2026: Can Cell Therapy Be The Future Of Autism Treatment?

What Is Herpes?

The herpes simplex virus (HSV) is very common, and the infection is lifelong. But the symptoms can come and go over different periods of life. Many people never get any symptoms linked to their infection.

The common virus, carried by up to 50 to 80 percent of adults, can cause painful blisters or ulcers. It primarily spreads by skin-to-skin contact. It is treatable but not curable.

There are two types of herpes simplex virus: HSV-1 and HSV-2.

HSV- 1 is the most common and usually spreads by oral contact. It causes infections in or around the mouth (such as oral herpes or cold sores), as well as genital herpes.

Common oral herpes symptoms include

• blisters (cold sores)
• open sores (ulcers) in or around the mouth or lips.

HSV-2 generally spreads by sexual contact and causes genital herpes.

Its symptoms include painful

• bumps,
• blisters,
• open sores (ulcers) around the genitals or anus.

How Makeup Testers Can Spread Infection

Experts warned that makeup testers can become a breeding ground for germs. The repeated use of the open samples can spur their growth and can then spread by “double-dipping” — reusing an applicator after touching the skin. This can transfer viruses and bacteria between users.

“You can absolutely get a herpes infection from a makeup tester," Dr. Whitney Bowe, a dermatologist in New York City, told TODAY. "The more ‘double dipping’ that occurs, the higher the chance of spreading viruses or bacteria at a makeup counter.”

A 2010 study by researchers from Rowan University in New Jersey found that cosmetic samples harbored strep, E.coli, and staph.

For two years, the team examined makeup testers at makeup counters, specialty stores, and drug stores. They found that Saturday is the busiest day of the week, and 100 percent of the samples carried some sort of germ.

How To Stay Safe?

To reduce the risk of infection, experts recommend:

• Much like the toothbrush, personal cosmetics and cosmetic brushes must not be shared.
• Wash and dry your brushes regularly to avoid bacterial growth.
• Avoid applying testers directly to your lips or skin
• Use disposable applicators
• Test products on your hand rather than your face
• Avoid using testers if you have cuts, chapped lips, or active infections.